We break down five key pharma news stories in a week that was dominated by the FDA's controversial approval of Biogen's Aduhelm and the annual meeting of the American Society for Clinical Oncology (ASCO).
Aducanumab controversy #1 – approval
Aducanumab controversy #2 – pricing
More Aduhelm analysis –
Cancer therapies move upstream at ASCO
A closer look at LAG-3
Could Bristol Myers Squibb's Zeposia benefit form JAK caution in UC?
To read more Friday Five articles, click here.